Eduardo V Davila

US Patent:

20130287752, Oct 31, 2013

Filed:

Dec 14, 2011

Appl. No.:

13/993396

Inventors:

Eduardo Davila - Cockeysville MD, US
Koji Tamada - Ube City, JP

Assignee:

UNIVERSITY OF MARYLAND, BALTIMORE - Baltimore MD

International Classification:

A61K 35/14

US Classification:

424 9371

Abstract:

The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αFITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of αFITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.

US Patent:

20130280264, Oct 24, 2013

Filed:

Mar 14, 2013

Appl. No.:

13/804135

Inventors:

Eduardo Davila - Cockeysville MD, US

International Classification:

C12Q 1/68
G01N 33/68
A61K 45/06
A61K 39/395

US Classification:

4241421, 435 29, 53038815, 435 74, 506 9, 435 612, 435 723

Abstract:

Toll-like receptors (TLR) are expressed by a variety of cancers, including melanoma and T-ALL. TLR signaling plays an important role in T cell malignancies and melanoma. The effects of stimulating or inhibiting the TLR/IL-1 receptor-associated kinases IRAK-1 and IRAK-4 in melanoma and T-ALL cells were evaluated. Pharmacological treatment with an IRAK-1,-4 inhibitor delays tumor growth and prolongs survival in vitro and in vivo, indicating that TLR signaling contributes to T-ALL and melanoma progression and interfering with this signaling is a novel therapeutic strategy to control T-ALL and melanoma proliferation.

US Patent:

20180282391, Oct 4, 2018

Filed:

Nov 6, 2015

Appl. No.:

15/524887

Inventors:

Eduardo DAVILA - Cockeysville MD, US

Assignee:

University of Maryland, Baltimore - Baltimore MD

International Classification:

C07K 14/705
C07K 14/47
C07K 14/73
C07K 14/725
A61K 35/17
A61P 35/00

Abstract:

Novel costimulatory fusion proteins and DNA sequences that enhance T cell responses to weakly immunogenic and/or lowly expressed antigens and that confer T cell resistance against MDSC-mediated suppression are disclosed. The fusion proteins comprise portions of CD4, CD8α or the T cell receptor linked to a specific region of MyD88 or other signaling molecules. These fusion proteins and sequence variants thereof improve T cell activation and responsiveness. Also disclosed is the use of these molecules in host cells as a means to enhance and costimulate responses of immune cells including cytotoxic CD8 T cells and the use of these cells to treat cancer, infectious agents and other diseases.